Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Receives $42.40 Consensus Target Price from Analysts

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) has earned a consensus recommendation of “Moderate Buy” from the fourteen brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $42.40.

Several analysts have recently weighed in on OLMA shares. Citigroup decreased their price objective on Olema Pharmaceuticals to $59.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Olema Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, August 17th. Wall Street Zen lowered shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, July 25th. Guggenheim dropped their price objective on shares of Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, HC Wainwright reduced their price objective on shares of Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating for the company in a report on Tuesday, August 11th.

Insider Transactions at Olema Pharmaceuticals

In related news, Director Cyrus Harmon sold 12,500 shares of the stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total value of $144,750.00. Following the completion of the transaction, the director owned 715,270 shares of the company’s stock, valued at $8,282,826.60. This represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 12.56% of the stock is owned by company insiders.

Institutional Investors Weigh In On Olema Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC raised its holdings in shares of Olema Pharmaceuticals by 9,476.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after buying an additional 1,232 shares in the last quarter. Torren Management LLC acquired a new stake in Olema Pharmaceuticals in the 4th quarter valued at $44,000. Russell Investments Group Ltd. bought a new stake in Olema Pharmaceuticals in the third quarter valued at $53,000. American Century Companies Inc. bought a new stake in Olema Pharmaceuticals in the second quarter valued at $54,000. Finally, Quantbot Technologies LP acquired a new position in Olema Pharmaceuticals during the second quarter worth $77,000. 91.78% of the stock is owned by institutional investors and hedge funds.

Olema Pharmaceuticals Stock Performance

NASDAQ:OLMA opened at $10.43 on Tuesday. The firm’s 50-day moving average is $11.46 and its 200-day moving average is $14.20. The company has a market cap of $912.62 million, a price-to-earnings ratio of -4.92 and a beta of 2.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.86 and a current ratio of 8.86. Olema Pharmaceuticals has a 52-week low of $5.36 and a 52-week high of $36.26.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, August 10th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.06). Equities research analysts anticipate that Olema Pharmaceuticals will post -2.43 earnings per share for the current year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.